DBV Technologies (NASDAQ:DBVT) — Market Cap & Net Worth
Market Cap & Net Worth: DBV Technologies (DBVT)
DBV Technologies (NASDAQ:DBVT) has a market capitalization of $740.98 Million ($740.98 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10306 globally and #2757 in its home market, demonstrating a -11.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying DBV Technologies's stock price $11.79 by its total outstanding shares 62848497 (62.85 Million). Also see DBVT asset base for a full breakdown of the balance sheet.
DBV Technologies Market Cap History: 2015 to 2026
DBV Technologies's market capitalization history from 2015 to 2026. Data shows change from $22.82 Billion to $740.98 Million (-26.40% CAGR). Also see DBV Technologies operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
DBV Technologies is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.03% | #292 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1068 of 3165 |
Weight: DBV Technologies's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
DBV Technologies Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how DBV Technologies's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check DBV Technologies share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
75.62x
DBV Technologies's market cap is 75.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $22.08 Billion | $7.93 Million | -$126.35 Million | 2785.25x | N/A |
| 2017 | $15.46 Billion | $11.52 Million | -$177.20 Million | 1342.19x | N/A |
| 2018 | $4.03 Billion | $12.81 Million | -$190.26 Million | 314.86x | N/A |
| 2019 | $6.72 Billion | $14.71 Million | -$172.01 Million | 457.22x | N/A |
| 2020 | $1.65 Billion | $11.28 Million | -$159.56 Million | 146.03x | N/A |
| 2021 | $1.01 Billion | $5.71 Million | -$97.81 Million | 176.17x | N/A |
| 2022 | $961.58 Million | $4.84 Million | -$96.27 Million | 198.51x | N/A |
| 2023 | $598.82 Million | $15.73 Million | -$72.73 Million | 38.07x | N/A |
| 2024 | $194.20 Million | $2.57 Million | -$113.72 Million | 75.62x | N/A |
Competitor Companies of DBVT by Market Capitalization
Companies near DBV Technologies in the global market cap rankings as of September 17, 2026. Review DBVT intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to DBV Technologies by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
DBV Technologies Historical Marketcap From 2015 to 2026
Between 2015 and today, DBV Technologies's market cap moved from $22.82 Billion to $ 740.98 Million, with a yearly change of -26.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $740.98 Million | -38.50% |
| 2025 | $1.20 Billion | +520.39% |
| 2024 | $194.20 Million | -67.57% |
| 2023 | $598.82 Million | -37.73% |
| 2022 | $961.58 Million | -4.38% |
| 2021 | $1.01 Billion | -38.93% |
| 2020 | $1.65 Billion | -75.51% |
| 2019 | $6.72 Billion | +66.67% |
| 2018 | $4.03 Billion | -73.90% |
| 2017 | $15.46 Billion | -29.97% |
| 2016 | $22.08 Billion | -3.25% |
| 2015 | $22.82 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of DBV Technologies was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $740.98 Million USD |
| MoneyControl | $740.98 Million USD |
| MarketWatch | $740.98 Million USD |
| marketcap.company | $740.98 Million USD |
| Reuters | $740.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more